High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

Teos (ITOS) stock is in focus as experimental cancer doublet therapy, developed with GSK, outperformed Jemperliin a mid-stage ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...

Kristen Foreman had an apple-sized mass near her left ovary, which was ovarian cancer. Doctors later discovered she had ...